Emma Walmsley, GlaxoSmithKline CEO (Mandel Ngan/AFP via Getty Images)
With a buyout, planned spinout and late-stage readouts, GSK promises this will be a landmark year
GlaxoSmithKline CEO Emma Walmsley has the Q1 sales numbers to start off what she says will be a landmark year. But delivering on the rest …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
